Abraham Garfinkel, MD
Family Medicine · Monticello, NYNPI 1962598490
Payments from drug & device makers
Across 302 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Orexo US, Inc.$541
- Lilly USA, LLC$540
- Axsome Therapeutics, Inc.$423
- Pfizer$422
- AbbVie$343
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,74198%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $1,438 |
| Orexo US, Inc. | 27 | $541 |
| Lilly USA, LLC | 34 | $540 |
| Axsome Therapeutics, Inc. | 20 | $423 |
| Pfizer | 19 | $422 |
| AbbVie(2 entities) | 16 | $343 |
| GSK | 12 | $219 |
| Exact Sciences | 9 | $217 |
| Jazz Pharmaceuticals Inc. | 11 | $178 |
| Amgen | 9 | $176 |
| Braeburn Inc. | 7 | $162 |
| Novo Nordisk | 8 | $126 |
| Antares Pharma, Inc. | 6 | $120 |
| Astellas Pharma US Inc | 4 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $102 |
| Johnson & Johnson | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Insulet Corporation | 3 | $72 |
| Amarin Pharma, Inc. | 4 | $69 |
| Halozyme Inc | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Corium, LLC | 3 | $49 |
| Mylan Specialty L.p. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Novartis | 2 | $34 |
| Eisai Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Merck | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$5,830 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $83,627 |
| EliquisApixaban | 56 | $47,586 |
| TrulicityDulaglutide | 22 | $44,312 |
| TradjentaLinagliptin | 34 | $42,491 |
| XareltoRivaroxaban | 45 | $35,692 |
| EntrestoSacubitril/Valsartan | 31 | $33,998 |
| MounjaroTirzepatide | 16 | $32,435 |
| OzempicSemaglutide | 17 | $30,402 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $30,311 |
| FarxigaDapagliflozin Propanediol | 20 | $25,392 |
| JanuviaSitagliptin Phosphate | 22 | $24,373 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $21,705 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $21,646 |
| LinzessLinaclotide | 26 | $17,693 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $16,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $34 | $156,429132 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $540 | $76,74738 claims |
| MerckJanuvia, Janumet, Janumet Xr | $18 | $62,97163 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta | $219 | $48,604144 claims |
| PfizerEliquis | $422 | $47,58656 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,438 | $39,84643 claims |
| Johnson & JohnsonXarelto | $77 | $35,69245 claims |
| NovartisEntresto | $34 | $33,99831 claims |
| AbbVieLinzess, Vraylar | $343 | $32,84037 claims |
| Novo NordiskOzempic | $126 | $30,40217 claims |
| Orexo US, Inc.Zubsolv | $541 | $9,58111 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $19 | $5,62512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Monticello
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.